Recent advances in the pathogenesis of Parkinson disease: α-synuclein and oxidative stress

Chinese Journal of Neuroscience

Volumn 20, Issue 4, 2004, Pages 327-331

  Qi, Chen ^a   Liu, Zhen Guo ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

synuclein; Oxidative stress; Parkinson disease; Pathogenesis

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE;

AGING; DEGENERATIVE DISEASE; ENVIRONMENTAL FACTOR; HEREDITY; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; REVIEW;

EID: 4644234155     PISSN: 10080872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Kessler JC, Rochet JC, Lansbury PT Jr. The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation [J]. Biochemistry, 2003, 42(3): 672-678.
2. Eliezer D, Kutluay E, Bussell R Jr, et al. Conformational properties of alpha-synuclein in its free and lipid-associated states [J]. J Mol Biol, 2001, 307(4): 1061-1073.
3. Schlossmacher MG, Frosch MP, Gai WP, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies [J]. Am J Pathol, 2002, 160(5): 1655-1667.
4. Bucciantini M, Giannoni E, Chiti F, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases [J]. Nature, 2002, 416(6880): 507-511.
5. Kirik D, Annett LE, Burger C, et al. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease [J]. Proc Natl Acad Sci USA, 2003, 100(5): 2884-2889.
6. Sharon R, Bar-Joseph I, Frosch MP, et al. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease [J]. Neuron, 2003, 37(4): 583-595.
7. Rideout HJ, Larsen KE, Sulzer D, et al. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells [J]. J Neurochem, 2001, 78(4): 899-908.
8. Tanaka Y, Engelender S, Igarashi S, et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis [J]. Hum Mol Genet, 2001, 10(9): 919-926.
9. Snyder H, Mensah K, Theisler C, et al. Aggregated and monomeric alpha-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function [J]. J Biol Chem, 2003, 278(14): 11753-11759.
10. McNaught KS, Belizaire R, Isacson O, et al. Altered proteasomal function in sporadic Parkinson's disease [J]. Exp Neurol, 2003, 179(1): 38-46.
11. McNaught KS, Mytilineou C, Jnobaptiste R, et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures [J]. J Neurochem, 2002, 81(2): 301-306.
12. McNaught KS, Bjorklund LM, Belizaire R, et. al. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats [J]. Neuroreport, 2002, 13(11): 1437-1441.
13. Junn E, Mouradian MM. Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases [J]. J Neurochem, 2001, 78(2): 374-383.
14. Junn E, Mouradian MM. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine [J]. Neurosci Lett, 2002, 320(3): 146-150.
15. Volles MJ, Lansbury PT Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism [J]. Biochemistry, 2002, 41(14): 4595-4602.
16. Tabner BJ, Turnbull S, El-Agnaf OM, et al. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease [J]. Free Radic Biol Med, 2002, 32 (11): 1076-1083.
17. Sherer TB, Kim JH, Betarbet R, et al. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation [J]. Exp Neurol, 2003, 179(1): 9-16.
18. Sherer TB, Betarbet R, Stout AK, et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage [J]. J Neurosci, 2002, 22(16): 7006-7015.
19. Dauer W, Kholodilov N, Vila M, et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP [J]. Proc Natl Acad Sci USA, 2002, 99(22): 14524-14529.